Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nutrition
Published in: European Journal of Nutrition 1/2013

01-02-2013 | Original Contribution

Principal component 1 score calculated from metabolic syndrome diagnostic parameters is a possible marker for the development of metabolic syndrome in middle-aged Japanese men without treatment for metabolic diseases

Authors: Kazuki Mochizuki, Rie Miyauchi, Yasumi Misaki, Yoko Ichikawa, Toshinao Goda

Published in: European Journal of Nutrition | Issue 1/2013

Login to get access

Abstract

Purpose

The risk of metabolic syndrome (MetS) is assessed based on the presence of risk factors that include dyslipidemia, hyperglycemia, hypertension and obesity. In this study, we assessed the risk of MetS using principle component (PC) analysis of MetS diagnostic parameters and examined whether the resulting eigenvalues are associated with the circulating concentrations of inflammatory cytokines [interleukin (IL)-1β and IL-6] and a marker for insulin sensitivity (adiponectin) in middle-aged Japanese men without treatment for metabolic diseases.

Materials

We conducted a cross-sectional study of 308 Japanese men without treatment for metabolic diseases aged 40–69 years who participated in health checkups in Japan. We calculated the PC1 score from the following MetS diagnostic parameters: body mass index (BMI), fasting blood glucose, diastolic blood pressure, triacylglycerol and high-density lipoprotein cholesterol. We compared the relationship between PC1 scores and other clinical parameters, including IL-1β, IL-6 and adiponectin, by Spearman’s rank correlation coefficient analyses and Jonckheere–Terpstra test.

Results

The associations for most clinical parameters were higher with the PC1 score than with other MetS diagnostic parameters. Homeostasis model assessment–insulin resistance, an index of insulin resistance, showed stronger associations with PC1 score than with MetS diagnostic parameters. Significant associations for IL-1β, IL-6 and adiponectin were observed with the PC1 score, BMI and triacylglycerol; these associations were higher with the PC1 score than with BMI and triacylglycerol.

Conclusions

The present results show that the PC1 score is closely associated with parameters of MetS, inflammation and insulin resistance.
Literature
1.
Vettor R, Milan G, Rossato M, Federspil G (2005) Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 22(suppl 2):3–10CrossRef
2.
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865):813–820CrossRef
3.
Ceriello A, Motz E (2004) Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24(5):816–823CrossRef
4.
Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21(6):697–738CrossRef
5.
Perrini S, Leonardini A, Laviola L, Giorgino F (2008) Biological specificity of visceral adipose tissue and therapeutic intervention. Arch Physiol Biochem 114(4):277–286CrossRef
6.
Smith SC Jr (2007) Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 120(3 suppl 1):S3–S11CrossRef
7.
Kokubo Y, Kamide K (2009) High-normal blood pressure and the risk of cardiovascular disease. Circ J 73(8):1381–1385CrossRef
8.
Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, Iida M, Kiyohara Y (2010) Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population The Hisayama study. Stroke 41(2):203–209
9.
Choo KE, Lau KB, Davis WA, Chew PH, Jenkins AJ, Davis TM (2007) Cardiovascular risk factors in pre-pubertal Malays: effects of diabetic parentage. Diabetes Res Clin Pract 76(1):119–125CrossRef
10.
Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS, Thomas GN, Tomlinson B (2001) Factor analysis of the metabolic syndrome: obesity vs. insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 25(12):1782–1788CrossRef
11.
Hanley AJ, Karter AJ, Festa A, D’Agostino R Jr, Wagenknecht LE, Savage P, Tracy RP, Saad MF, Haffner S (2002) Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the insulin resistance atherosclerosis study. Diabetes 51(8):2642–2647CrossRef
12.
Esteghamati A, Zandieh A, Khalilzadeh O, Meysamie A, Ashraf H (2010) Clustering of metabolic syndrome components in a Middle Eastern diabetic and non-diabetic population. Diabetol Metab Syndr 2:36
13.
Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 52(3):812–817CrossRef
14.
Kim ES, Im JA, Kim KC, Park JH, Suh SH, Kang ES, Kim SH, Jekal Y, Lee CW, Yoon YJ, Lee HC, Jeon JY (2007) Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth. Obesity (Silver Spring) 15(12):3023–3030CrossRef
15.
Bruun JM, Stallknecht B, Helge JW, Richelsen B (2007) Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol 157(4):465–471CrossRef
16.
Hoge M, Amar S (2006) Role of interleukin-1 in bacterial atherogenesis. Drugs Today (Barc) 42(10):683–688CrossRef
17.
Mahmoudi M, Curzen N, Gallagher PJ (2007) Atherogenesis: the role of inflammation and infection. Histopathology 50(5):535–546CrossRef
18.
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148(2):209–214CrossRef
19.
Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, Mohan V (2006) Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance—The Chennai Urban Rural Epidemiology Study (CURES). Metabolism 55(9):1232–1238CrossRef
20.
Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, Sugiura K, Kondo T, Murohara T, Toyoshima H (2006) Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26(4):871–876CrossRef
21.
Misaki Y, Miyauchi R, Mochizuki K, Takabe S, Shimada M, Ichikawa Y, Goda T (2010) Plasma IL-1β concentrations are closely associated with fasting blood glucose levels in healthy and preclinical middle-aged, non-overweight and overweight Japanese men. Metabolism 59(10):1465–1471CrossRef
22.
Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85(9):3338–3342CrossRef
23.
Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala MW, Du X, Rollman B, Li W, Hawkins M, Barzilai N, Rhodes CJ, Fantus IG, Brownlee M, Scherer PE (2005) The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 280(6):4617–4626CrossRef
24.
Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8(11):1288–1295CrossRef
25.
Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27(10):2450–2457CrossRef
26.
Gottsater A, Szelag B, Kangro M, Wroblewski M, Sundkvist G (2004) Plasma adiponectin and serum advanced glycated end-products increase and plasma lipid concentrations decrease with increasing duration of type 2 diabetes. Eur J Endocrinol 151(3):361–366CrossRef
27.
Mannucci E, Ognibene A, Cremasco F, Dicembrini I, Bardini G, Brogi M, Terreni A, Caldini A, Messeri G, Rotella CM (2003) Plasma adiponectin and hyperglycaemia in diabetic patients. Clin Chem Lab Med 41(9):1131–1135CrossRef
28.
Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26(8):2442–2450CrossRef
29.
Sakuta H, Suzuki T, Yasuda H, Ito T (2005) Adiponectin levels and cardiovascular risk factors in Japanese men with type 2 diabetes. Endocr J 52(2):241–244CrossRef
30.
Jaleel F, Jaleel A, Aftab J, Rahman MA (2006) Relationship between adiponectin, glycemic control and blood lipids in diabetic type 2 postmenopausal women with and without complication of ischemic heart disease. Clin Chim Acta 370(1–2):76–81CrossRef
31.
Suzuki T, Katz R, Jenny NS, Zakai NA, LeWinter MM, Barzilay JI, Cushman M (2008) Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 1(4):242–248CrossRef
32.
Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Hegele RA, Retnakaran R, Zinman B, Hanley AJ (2008) Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care 31(7):1410–1415CrossRef
33.
Taniguchi A, Fukushima M, Ohya M, Nakai Y, Yoshii S, Nagasaka S, Matsumoto K, Taki Y, Kuroe A, Nishimura F, Seino Y (2006) Interleukin 6, adiponectin, leptin, and insulin resistance in nonobese Japanese type 2 diabetic patients. Metabolism 55(2):258–262CrossRef
34.
Higashiyama A, Okamura T, Ono Y, Watanabe M, Kokubo Y, Okayama A (2009) Risk of smoking and metabolic syndrome for incidence of cardiovascular disease—Comparison of relative contribution in urban Japanese population: the Suita study. Circ J 73(12):2258–2263CrossRef
35.
Kadota A, Miura K, Okamura T, Hozawa A, Murakami Y, Fujiyoshi A, Takashima N, Hayakawa T, Kita Y, Okayama A, Nakamura Y, Ueshima H (2011) Relationship of moderate metabolic risk factor clustering to cardiovascular disease mortality in non-lean Japanese: a 15-year follow-up of NIPPON DATA90. Atherosclerosis 215(1):209–213CrossRef
36.
Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ishibashi S, Katayama S, Saito Y, Ito H, Ohashi Y, Akanuma Y, Yamada N (2005) Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 28(6):1463–1471CrossRef
37.
Suzuki A, Kosuge K, Nanyu O, Watanabe H, Watanabe T, Usuda Y, Sasaki S, Aizawa Y (2010) Five year study of cardiovascular risk factors in Japanese people: implications concerning new onset of metabolic syndrome. Intern Med 49(1):1–6CrossRef
38.
Doi Y, Ninomiya T, Hata J, Yonemoto K, Arima H, Kubo M, Tanizaki Y, Iwase M, Iida M, Kiyohara Y (2009) Proposed criteria for metabolic syndrome in Japanese based on prospective evidence: the Hisayama study. Stroke 40(4):1187–1194CrossRef
39.
Nakanishi N, Takatorige T, Fukuda H, Shirai K, Li W, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K (2004) Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 64(1):59–70CrossRef
Metadata
Title
Principal component 1 score calculated from metabolic syndrome diagnostic parameters is a possible marker for the development of metabolic syndrome in middle-aged Japanese men without treatment for metabolic diseases
Authors
Kazuki Mochizuki
Rie Miyauchi
Yasumi Misaki
Yoko Ichikawa
Toshinao Goda
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
European Journal of Nutrition / Issue 1/2013
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-011-0287-z

Other articles of this Issue 1/2013

European Journal of Nutrition 1/2013 Go to the issue

Original Contribution

Alterations in peripheral purinergic and muscarinic signaling of rat bladder after long-term fructose-induced metabolic syndrome

Original Contribution

The effect of plant sterols on serum triglyceride concentrations is dependent on baseline concentrations: a pooled analysis of 12 randomised controlled trials

Original Contribution

Relationship between the body adiposity index and cardiometabolic risk factors in obese postmenopausal women

Original Contribution

Regulation of iron metabolism in Hamp −/− mice in response to iron-deficient diet

Original Contribution

Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model

Original Contribution

Neuroprotective effects of digested polyphenols from wild blackberry species
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits